Clinical Testing News and Research

RSS

ACT Biotech's Telatinib receives orphan drug designation from FDA for treatment of gastric cancer

ACT Biotech Inc., a privately held biotechnology company developing a portfolio of oral kinase inhibitors as anti-cancer drugs, announced today that the company's highly selective oral kinase inhibitor, Telatinib, has received orphan drug designation from the U.S. Food and Drug Administration for the treatment of gastric cancer.

3 Jun 2010

Insulin pills to manage diabetes are finally moving ahead in clinical trials

After years of research and anticipation, insulin pills that could make it easier for millions of patients worldwide to manage diabetes are finally moving ahead in clinical trials and a step-closer to the medicine cabinet. That's among the topics highlighted in a two-part cover story on drug manufacturing in the current issue of Chemical & Engineering News, ACS' weekly newsmagazine.

3 Jun 2010

U.S. Department of Defense OTT initiative to replace scars and defects with healthy, functional tissues

A two-year, $12 million contract with the U.S. Department of Defense Office of Technology Transition (OTT) will jumpstart human trials of three innovative research programs that aim to replace scars and defects with healthy, functional tissues, announced officials of the University of Pittsburgh and the McGowan Institute for Regenerative Medicine today at the Institute's Second Annual Open Session, Soldiers and Sailors Memorial Hall, Oakland.

31 May 2010

CytRx commences Phase 2 clinical trial of bafetinib for high-risk B-cell chronic lymphocytic leukemia

CytRx Corporation, a biopharmaceutical company specializing in oncology, today announced initiation of a Phase 2 proof-of-concept clinical trial to evaluate the preliminary efficacy and safety of its oncology drug candidate bafetinib in patients with high-risk B-cell chronic lymphocytic leukemia (B-CLL).

29 May 2010

Covidien launches V-Loc 90 knotless wound closure device

Covidien, a leading global provider of healthcare products, today announced the global launch of the V-Loc 90 device, expanding its family of V-Loc absorbable wound closure devices. This latest addition to Covidien's knotless wound closure product line received 510(k) clearance from the U.S. Food and Drug Administration on May 11, 2010.

27 May 2010

New study holds promise for patients with LCA

A new study led by Dr. Robert Koenekoop at the Montreal Children's Hospital at the McGill University Health Centre holds promise for certain patients with Leber congenital amaurosis, an inherited retinal degenerative disease that causes significant vision loss from birth. The study, sponsored by Canadian company QLT Inc., is designed to treat patients with LCA due to genetic mutations in either retinal pigment epithelium protein 65 or lecithin:retinol acyltransferase.

27 May 2010

Five Prime Therapeutics, Fast Forward partner to develop Multiple Sclerosis therapeutic candidate

Five Prime Therapeutics, Inc., a leader in the discovery and development of innovative biologics, and Fast Forward, LLC, a subsidiary of the National Multiple Sclerosis Society, today announced an alliance to fund the development of a FivePrime pre-clinical stage therapeutic candidate for treatment of Multiple Sclerosis (MS). Fast Forward will commit up to $1 million to fund the advancement of the therapeutic candidate.

25 May 2010

ADDF provides $248,000 grant to ALSP to allow its lead drug candidate towards clinical trials

The Alzheimer's Drug Discovery Foundation announced today that it is providing a grant of $248,000 to American Life Science Pharmaceuticals, Inc. to allow for manufacture of its lead drug candidate to be used in preclinical toxicology testing in preparation for entering Phase I clinical trials early in 2011.

25 May 2010

Inviragen initiates first clinical trial of DENVax vaccine to protect against dengue fever

Inviragen has announced the initiation of the first clinical trial of its vaccine to protect against dengue fever. The trial, to be conducted at Saint Louis University, is designed to assess the safety of Inviragen's investigational dengue vaccine.

20 May 2010

Pfizer, Washington University announce indications discovery collaboration

In a first-of-a-kind collaboration between academia and industry, Pfizer Inc. will give scientists at Washington University School of Medicine in St. Louis unprecedented access to information regarding more than 500 pharmaceuticals and pharmaceutical candidates in a partnership that focuses on discovering new uses for existing compounds.

18 May 2010

Researchers identify protein involved in pushing bladder tumors to become invasive

Bladder cancer often becomes aggressive and spreads in patients despite treatment, but now researchers at the Kimmel Cancer Center at Jefferson have identified a protein they believe is involved in pushing tumors to become invasive - and deadly.

15 May 2010

ULURU reports net loss of $1.3M for first-quarter 2010

ULURU Inc. today announced its financial results for the first quarter ended March 31, 2010.

14 May 2010

IVAX Diagnostics first-quarter net revenues decline 1.4% to $4,655,000

IVAX Diagnostics, Inc., a fully integrated in vitro diagnostics company, reports its financial results for the quarter ended March 31, 2010.

14 May 2010

ISCA recommends chromosomal microarray as new standard for genetic evaluation of children

An international consortium of genetics experts has issued a consensus statement recommending chromosomal microarray (CMA) as the new standard practice for genetic evaluation of children with unexplained developmental delay, autism or birth defects.

14 May 2010

Progenics Pharmaceuticals reports net loss of $18.6M in first-quarter 2010

Progenics Pharmaceuticals, Inc. today announced its results of operations for the quarter ended March 31, 2010.

11 May 2010

Bovie Medical first-quarter revenues decrease to $5.6M

Bovie Medical Corporation, a manufacturer and marketer of electrosurgical products, today announced its financial results for the first quarter ended March 31, 2010.

10 May 2010

Telemedical Retinal Image Analysis and Diagnosis technology permits early detection of diabetic retinopathy

Automated Medical Diagnostics, a startup company based in Memphis, envisions its product helping to preserve the sight of millions of people at risk of vision loss from diabetic retinopathy.

7 May 2010

Momenta Pharmaceuticals first-quarter net loss decreases to $16.1 million

Momenta Pharmaceuticals, Inc., a biotechnology company specializing in the characterization and engineering of complex drugs, today reported its financial results for the quarter ended March 31, 2010.

6 May 2010

S*BIO, Onyx Pharmaceuticals expand development, commercialization collaboration for JAK2 Inhibitors

S*BIO Pte Ltd and Onyx Pharmaceuticals, Inc. today announced the expansion of their development collaboration and option and license commercialization agreement for S*BIO's novel JAK2 inhibitors, SB1518 and SB1578, also known as ONX 0803 and ONX 0805, respectively. The expanded agreement builds upon the development and commercialization collaboration between the two companies announced in January 2009.

5 May 2010

NOXXON Pharma completes first-in-human clinical trial with Spiegelmer NOX-A12

NOXXON Pharma AG, the biopharmaceutical company focusing on the development of novel drugs based on its unique proprietary Spiegelmer® technology, announced today the successful completion of the first-in-human clinical trial with Spiegelmer® NOX-A12.

3 May 2010

Clinical Testing News and Research

ACT Biotech's Telatinib receives orphan drug designation from FDA for treatment of gastric cancer

Insulin pills to manage diabetes are finally moving ahead in clinical trials

U.S. Department of Defense OTT initiative to replace scars and defects with healthy, functional tissues

CytRx commences Phase 2 clinical trial of bafetinib for high-risk B-cell chronic lymphocytic leukemia

Covidien launches V-Loc 90 knotless wound closure device

New study holds promise for patients with LCA

Five Prime Therapeutics, Fast Forward partner to develop Multiple Sclerosis therapeutic candidate

ADDF provides $248,000 grant to ALSP to allow its lead drug candidate towards clinical trials

Inviragen initiates first clinical trial of DENVax vaccine to protect against dengue fever

Pfizer, Washington University announce indications discovery collaboration

Researchers identify protein involved in pushing bladder tumors to become invasive

ULURU reports net loss of $1.3M for first-quarter 2010

IVAX Diagnostics first-quarter net revenues decline 1.4% to $4,655,000

ISCA recommends chromosomal microarray as new standard for genetic evaluation of children

Progenics Pharmaceuticals reports net loss of $18.6M in first-quarter 2010

Bovie Medical first-quarter revenues decrease to $5.6M

Telemedical Retinal Image Analysis and Diagnosis technology permits early detection of diabetic retinopathy

Momenta Pharmaceuticals first-quarter net loss decreases to $16.1 million

S*BIO, Onyx Pharmaceuticals expand development, commercialization collaboration for JAK2 Inhibitors

NOXXON Pharma completes first-in-human clinical trial with Spiegelmer NOX-A12

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

Latest News